Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (101-110 of 377) with videos related to

Pageof 38
Sort By:
Critical Reviews in Oncology/Hematology|July 13, 2024
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to successLorenzo Belluomini, Alice Avancini, Marco Sposito, et al.
Cancer Treatment Reviews|June 13, 2006
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patientsEmilio Bria, Mariangela Ciccarese, Diana Giannarelli, et al.
Minerva Surgery|August 2, 2021
Validation of a prognostic model including the number of harvested lymph-nodes in the setting of non-small cell lung cancer patients undergoing curative resection: a multicenter analysisMarco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Expert Opinion on Biological Therapy|November 8, 2008
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issuesEmilio Bria, Federica Cuppone, Michele Milella, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|September 12, 2018
Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†Marco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Expert Review of Anticancer Therapy|June 13, 2020
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectivesGiulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Current Pharmaceutical Design|October 22, 2013
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'Sara Pilotto, Maria Bonomi, Francesco Massari, et al.
Clinical Lung Cancer|May 12, 2020
Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter AnalysisMarco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Cancer|June 29, 2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinomaMichele Milella, Alain Gelibter, Serena Di Cosimo, et al.
Pageof 38

Showing results (101-110 of 377) with videos related to

Sort By:
Pageof 38
Critical Reviews in Oncology/Hematology|July 13, 2024
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to successLorenzo Belluomini, Alice Avancini, Marco Sposito, et al.
Cancer Treatment Reviews|June 13, 2006
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patientsEmilio Bria, Mariangela Ciccarese, Diana Giannarelli, et al.
Minerva Surgery|August 2, 2021
Validation of a prognostic model including the number of harvested lymph-nodes in the setting of non-small cell lung cancer patients undergoing curative resection: a multicenter analysisMarco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Expert Opinion on Biological Therapy|November 8, 2008
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issuesEmilio Bria, Federica Cuppone, Michele Milella, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|September 12, 2018
Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†Marco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Expert Review of Anticancer Therapy|June 13, 2020
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectivesGiulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Current Pharmaceutical Design|October 22, 2013
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'Sara Pilotto, Maria Bonomi, Francesco Massari, et al.
Clinical Lung Cancer|May 12, 2020
Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter AnalysisMarco Chiappetta, Giovanni Leuzzi, Isabella Sperduti, et al.
Cancer|June 29, 2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinomaMichele Milella, Alain Gelibter, Serena Di Cosimo, et al.
Pageof 38